Bain Capital Life Sciences Investors as of June 30, 2024
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 25 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 22.5 | $205M | 2.7M | 75.86 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 22.1 | $201M | 11M | 19.21 | |
| Disc Medicine (IRON) | 8.9 | $81M | 1.8M | 45.07 | |
| Dianthus Therapeutics (DNTH) | 8.6 | $78M | 3.0M | 25.88 | |
| Pharvaris N V (PHVS) | 6.8 | $62M | 3.3M | 18.80 | |
| Savara (SVRA) | 6.4 | $59M | 15M | 4.03 | |
| Annexon (ANNX) | 4.5 | $41M | 8.4M | 4.90 | |
| Kyverna Therapeutics (KYTX) | 2.8 | $25M | 3.4M | 7.50 | |
| Tango Therapeutics (TNGX) | 2.7 | $25M | 2.9M | 8.58 | |
| Solid Biosciences Com New (SLDB) | 2.5 | $23M | 4.0M | 5.67 | |
| Mersana Therapeutics | 1.9 | $17M | 8.7M | 2.01 | |
| Syros Pharmaceuticals Com New (SYRS) | 1.6 | $14M | 2.7M | 5.16 | |
| Century Therapeutics (IPSC) | 1.5 | $14M | 5.4M | 2.55 | |
| Cabaletta Bio (CABA) | 1.4 | $12M | 1.6M | 7.48 | |
| X4 Pharmaceuticals | 1.1 | $9.8M | 17M | 0.58 | |
| Arcutis Biotherapeutics (ARQT) | 1.1 | $9.6M | 1.0M | 9.30 | |
| Atea Pharmaceuticals (AVIR) | 0.9 | $8.2M | 2.5M | 3.31 | |
| Rapid Micro Biosystems Class A Com (RPID) | 0.6 | $5.6M | 8.4M | 0.66 | |
| C4 Therapeutics Com Stk (CCCC) | 0.6 | $5.1M | 1.1M | 4.62 | |
| Nautilus Biotechnology (NAUT) | 0.5 | $4.7M | 2.0M | 2.34 | |
| Xilio Therapeutics (XLO) | 0.4 | $3.6M | 3.8M | 0.95 | |
| Marinus Pharmaceuticals Com New | 0.3 | $2.7M | 2.3M | 1.17 | |
| Adagio Therapeutics (IVVD) | 0.2 | $2.0M | 1.8M | 1.10 | |
| Aclaris Therapeutics (ACRS) | 0.1 | $1.1M | 1.0M | 1.10 | |
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.1 | $872k | 100k | 8.72 |
